ABSTRACT: Background. Substantial health care resources are used on aggressive end-of-life care, despite an increasing recognition that palliative care improves quality of life and reduces health care costs. We examined the incidence of palliative care encounters in inpatients with incurable head and neck cancer and associations with in-hospital mortality, length of hospitalization, and costs. Methods. Data from the Nationwide Inpatient Sample (NIS) for 80,514 head and neck cancer patients with distant metastatic disease in 2001 to 2010 was analyzed using cross-tabulations and multivariate regressions. Results. Palliative care encounters occurred in 4029 cases (5%) and were significantly associated with age 80 years, female sex, self-pay payor status, and prior radiation. Palliative care was significantly associated with increased in-hospital mortality and reduced hospital-related costs. Conclusion. Inpatient palliative care consultation in terminal head and neck cancer is associated with reduced hospital-related costs, but appears to be underutilized and restricted to the elderly, uninsured, and patients with an increased risk of mortality.
INTRODUCTION
A substantial amount of health care resources are used on aggressive end-of-life care, with 7% of the total Medicare budget spent in the last month of life alone. 1 These patterns of care can be improved with an integration of palliative care into end-of-life care, which improves quality of life, patient and caregiver satisfaction, and reduces health care costs. 2 The National Comprehensive Cancer Network (NCCN) and National Consensus Project for Quality Palliative Care recommend that physicians discuss end-of-life planning with patients with incurable cancer and a life expectancy of less than 1 year. 3, 4 Patients who have discussed end-oflife care with their physicians are more likely to choose palliation over aggressive care, defined as chemotherapy in the last 14 days of life, acute hospital-based care in the last 30 days of life, or intensive care unit (ICU) care in the last 30 days of life. 5 Such patients are more likely to receive hospice care and have hospice care initiated earlier, and are more likely to die at home or in hospice care. Less aggressive care at the end-of-life is associated with better quality of life; however, fewer than 40% of patients have end-of-life discussions with their physicians. 6 The goal of palliative care, according to NCCN guidelines, "is to anticipate, prevent, and reduce suffering" and such care "begins at diagnosis and should be delivered concurrently with disease-directed, life-prolonging therapies." 3 Palliative care is offered earlier in the disease process than hospice care and is given in addition to cancer treatment for physical and emotional symptom support. Although palliative care services can be provided by the treating physician, increasingly, palliative care specialists work as part of a multidisciplinary team to coordinate care and make recommendations. Head and neck cancer causes significant morbidity, mortality, and unique end-of-life issues that necessitate the incorporation of palliative care. The majority of patients with advanced head and neck cancer have significant pain. Airway complications, communication deficits, intolerance to oral intake, disfigurement, and psychosocial issues are among the other challenging palliative care issues that result from head and neck cancer. 7 Despite this need, there is a paucity of data regarding end-of-life and palliative care in head and neck cancer. We sought to determine the incidence of palliative care consultations among patients hospitalized with a diagnosis of metastatic, incurable head and neck cancer and the relationship between palliative care encounters and in-hospital morbidity and mortality, length of hospitalization, and costs.
PATIENTS AND METHODS
A cross-sectional analysis of patients admitted with a diagnosis of oral cavity, laryngeal, hypopharyngeal, or oropharyngeal cancer who also had a diagnosis of distant metastatic disease was performed using discharge data from the Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project, and the Agency for Healthcare Research and Quality. The NIS is the largest allpayer in-patient care database in the United States, containing data from approximately 8 million hospital stays each year from a stratified sample of 20% of nonfederal U.S. hospitals from participating states. 8 The NIS database provides information regarding the index hospital admission and includes patient demographic data, primary and secondary diagnoses, primary and secondary procedures, hospital characteristics, and in-patient and discharge mortality rates. The International Classification of Disease, 9th revision (ICD-9) codes were used to identify adult patients (18 years of age) with a diagnosis of a malignant oral cavity, laryngeal, hypopharyngeal, or oropharyngeal neoplasm for the years 2001 through 2010, as previously described. 9 Patients who underwent a head and neck ablative procedure or neck dissection, as previously described, were excluded from this study. 9 Metastatic disease was identified using codes for secondary malignant neoplasm of respiratory and digestive systems (197.0-197.8), intrathoracic lymph nodes (196.1), intraabdominal lymph nodes (196.2), and other specified sites (198.0-198.8) . Patients with codes for secondary unspecified malignant neoplasm of cervical lymph nodes were excluded (196.0) because of inability to determine if this code represented terminal or curable disease.
In-patient palliative care encounters were identified using the ICD-9 code for encounter for palliative care (V66.7), which includes end-of-life care, hospice care, and terminal care. The American Hospital Association Coding Clinic for ICD-9-CM, 1Q 1998, volume 15(1):11 states the following: "Terms such as comfort care, endof-life care, and hospice care are all synonymous with palliative care. These, or similar terms, need to be written in the record to support the use of code V66.7."
10 Radiation therapy was identified using codes for therapeutic radiotherapy, including brachytherapy implantation (92. 21, 92.22, 92.25, 92.27, 92.28, and 92.29) , and chemotherapy was coded using codes for injection, infusion, or implantation of a chemotherapeutic agent (99.25, 99.28, 99.29, and 00.10). Prior irradiation was obtained from the codes for previous exposure to therapeutic or other ionizing radiation (V15.3). Comorbidity was graded using the Romano adaptation of the Charlson comorbidity index, [11] [12] [13] excluding ICD-9 codes for the index cancer diagnosis from the solid tumor category. Cancer staging information is not available in the NIS, and, as a result, ICD-9 codes for metastases were excluded as these have not been shown to be a reliable surrogate for disease stage.
14 Codes for specific comorbid illnesses were used to create categories for acute medical complications, as previously described, 9 Hospital-related charges for each index admission were converted to the organizational cost of providing care using cost to charge ratios for individual hospitals. Costto-charge ratios were calculated using information from the detailed reports by hospitals to the Centers for Medicare and Medicaid Services, providing an estimate of the all-payer in-patient cost-to-charge ratio by hospital. 15 This ratio was multiplied by each patient's charge to obtain the cost per admission. 16 All costs were adjusted for inflation based on U.S. Bureau of Labor Statistics indices, with results converted to 2012 U.S. dollars. 17 To obtain national cost estimates, all discharges were re-weighted to account for cases in which cost estimates were missing. 15 Data were analyzed using Stata 12 (StataCorp, College Station, TX). Associations between variables were analyzed using cross-tabulations and multivariate logistic regression modeling. Data were weighted and modified hospital and discharge weights to correct for changes in sampling over time were applied. Variance estimation was performed using procedures for survey data analysis with replacement. Strata with one sampling unit were centered at the population mean. Variables with missing data for more than 10% of the population were coded with a dummy variable to represent the missing data in regression analysis. The primary clinical endpoints were evaluated using multiple logistic regression analysis. Generalized linear regression modeling with a log link was used to analyze costs and length of stay because these variables were not normally distributed. This protocol was reviewed and approved by the Johns Hopkins Medical Institutions Institutional Review Board. 
RESULTS
There were 80,514 cases in 2001 to 2010 who met study criteria (Table 1) . The majority of patients were men, white, with a mean age of 62 years (range, 18-100 years). In-hospital death occurred in 9116 cases (11%) and a palliative care encounter was documented in 4029 cases (5%). A palliative care encounter was more likely in white patients, women, patients older than 80 years of age, with private insurance or self-pay payor status, with an acute medical comorbidity, and with a history of radiation therapy, but was less likely for patients who received chemotherapy or radiation therapy during admission. There was no association between the use of a palliative care encounter and hospital characteristics (size, volume, location, ownership, teaching status, or region), or ICU care. Palliative care encounters were significantly associated with a higher incidence of in-patient death or discharge to a nonacute care facility.
Multiple logistic regression analysis of predictor variables associated with cancer-directed care is shown in Table  2 . After controlling for all other variables, chemotherapy was significantly associated with a decreased likelihood of urgent or emergent admission, advanced age, comorbidity, or prior radiation, and was significantly more likely in patients with Medicaid, in urban locations, and increasing hospital volume. The use of radiation was significantly associated with a decreased likelihood of urgent or emergent admission or prior radiation, and was significantly more likely in urban locations, teaching hospitals, and increasing hospital volume. Palliative care during hospitalization was significantly associated with an increased likelihood of age greater than 80 years, female sex, self-pay payor status, and prior radiation, but was significantly less likely for patients with Medicare or Medicaid. There was no significant association between type of admission, comorbidity, race, hospital characteristics or location, and in-patient palliative care. Palliative care was significantly less likely in patients receiving chemotherapy (odds ratio [OR] 5 0.27; 95% confidence interval [CI] 5 0.18-0.38; p < .001) or radiation (OR 5 0.60; 95% CI 5 0.37-0.97; p 5 .037) during the same admission.
Multivariable logistic regression analysis of variables associated with short-term mortality, acute medical complications, and ICU care showed a significant association between palliative care and short-term mortality (OR 5 4.89; 95% CI 5 4.02-5.94; p < .001), after controlling for all other variables. There was no significant association between palliative care consultation and acute medical complications (OR 5 1.07; 95% CI 5 0.89-1.28; p 5 .423) or ICU care (OR 5 1.20; 95% CI 5 0.87-1.65; p 5 .254). However, there was a significant relationship between palliative care, chemotherapy administration, and acute medical complications, with a significantly and hospital-related costs are shown in Table 3 , with mean values representing the change in the value of the intercept mean. Medicaid insurance, comorbidity, black or Hispanic race, urban hospital location, and administration of chemotherapy or radiation were significantly associated with both increased length of hospitalization and hospital costs. Female sex, Medicare, self-pay payer status, and large hospital size were additionally associated with greater length of hospitalization. Palliative care was associated with significantly lower hospital-related costs but had no significant effect on length of hospitalization.
There was a significant interaction between palliative care, chemotherapy administration, and costs, with a mean incremental increase in costs of $6161 (ß 5 0.4562; 95% CI 5 0.1250-0.7875; p 5 .07) in patients receiving chemotherapy who also had palliative care involvement.
DISCUSSION
There has been an increasing trend of aggressive cancer treatment near the end of life despite a growing body of evidence that palliative care improves outcomes and reduces health care costs at the end of life. [18] [19] [20] [21] [22] [23] Patients with head and neck cancer bear a particularly high burden of morbidity and mortality and have unique palliative care needs resulting from the effects of both the disease process and treatment. 7, [24] [25] [26] [27] Despite the need for specialized end-of-life care, few studies have examined palliative and end-of-life care among patients with head and neck cancer. We undertook this analysis to examine trends associated with the use of in-patient palliative care services among patients with metastatic head and neck cancer.
In this study, among 80,514 hospital admissions for patients with metastatic head and neck cancer, palliative care as evidenced by the V66.7 code was documented in only 5% of cases. Palliative care encounters were less likely among patients receiving chemotherapy or radiation during the hospital admission. Patients with palliative care encounters had increased in-hospital mortality during the same admission, but incurred significantly lower hospital-related costs with no change in length of hospitalization. Of note, we could not determine if patients had a formal palliative care consultation done or not, as there is no "code" for that. Instead, we used the V66.7 code that is applied after discharge when coders search for words in the medical chart associated with hospice or palliative care. 28 To our knowledge, this is the first such use of this code to determine any potential use of palliative care. Given the extremely low rate of palliative care utilization at any time in patients with a similar disease -8% to 9% for patients with lung cancer and usually near the time of death, 29, 30 we think that the 5% use of the V66.7 code may well represent an overestimate of actual palliative care use.
In 2003, at the M.D. Anderson Cancer Center, a 400-bed cancer hospital, only 10 patients (2.5%) were admitted to the Palliative Care In-patient Service. 31 In a 982-bed German hospital in 2010, 6.9% and 9.1% of patients with cancer over 65 years of age had palliative care needs. 32 A point prevalence survey in 3 Australian hospitals showed that 35% were classifiable as "requiring a palliative approach" but only 22% of those patients were referred for palliative care -overall, a total of 7.7%. 33 A point prevalence study in Norway showed that 36% of all patients were classified as "palliative" as defined by "advanced, serious, chronic disease with limited life expectancy and symptom relief as the main goal of treatment." 34 The V66.7 code used in our study is uniformly recognized as the only diagnosis code specifically associated with palliative care, but may be used differently by hospital raters of quality. 35 Regardless of methodology, these data show that the use of palliative care remains low in a disease with a high symptom burden.
In 2012, the American Society of Clinical Oncology published a provisional clinical opinion to guide the integration of palliative care into standard oncology practice at the time of metastatic cancer diagnosis. 19 The NCCN also recommends early palliative care involvement as part of cancer care, and the Institute of Medicine's Committee on Improving the Quality of Cancer Care stated that "a primary emphasis" should be placed on providing palliative care to patients with advanced cancer. 3, 36 Along with growing acceptance of the importance of palliative care services, access to palliative care is improving. The general availability of in-patient palliative care teams at hospitals with over 50 beds increased from 24.5% in 2000 to 65.7% in 2010, with 81% of hospitals with over 300 beds having palliative care programs by 2010, which was the end of this study. 37 Despite these facts, the American Academy of Hospice and Palliative Care Medicine task force reported an acute shortage of palliative care physicians as recently as 2010, suggesting that lack of availability remains an issue. 38 We did observe an increase in the use of the V66.7 code during the time of our study, from 3.2% of cases in 2001 to 10.1% of cases in 2010, demonstrating a temporal trend of increasing utilization of in-patient palliative care services and suggesting an increase in hospital-based palliative care programs; it may also reflect an increasing awareness of the V66.7 code. Overall, however, our study suggests that palliative care remains underutilized, as only 5% of the patients in our study had evidence of palliative care involvement during in-patient hospital admission even after controlling for hospital size. As this study was confined to in-patients with incurable disease, these data suggest that palliative care services are not adequately being utilized to serve terminal patients with head and neck cancer who could most benefit.
The association between palliative care encounters and death during the same hospitalization suggests that inpatient palliative care consultation occurs late in the course of illness when patients begin to deteriorate medically and are close to death. A study by Earle et al 18 reported that among patients who received hospice care, hospice care was initiated in the last 3 days of life in an increasing proportion of patients during a 4-year period of time. In a study of Medicare patients enrolled in hospice, almost half died within 14 days of enrollment, 39 and a study of patients with head and neck cancer reported a mean time-to-death after hospice initiation of 19.5 days. 24 Dy et al 40 have reported that hospice utilization in Medicare patients was not associated with changes in the utilization of hospital services in the last year of life except in nursing home residents, and in chronically disabled patients, hospice utilization was not associated with a decrease in in-hospital deaths, which may be due to substantial resource investments and greater intensity of care. Our findings support the observation made by Earle et al 18 that despite an increase in palliative care utilization, in many cases, palliative care and hospice services are used to manage death at the time of death, rather than for palliation during a more substantial end-of-life period.
Patients receiving palliative care services in this study incurred significantly lower hospital costs. This finding is consistent with a substantial body of evidence demonstrating that palliative care and end-of-life discussions significantly lower costs of care. 6, 19, 21, 22, [41] [42] [43] [44] [45] We found that patients undergoing chemotherapy or radiation therapy were less likely to have a palliative care encounter, with the exception of patients undergoing chemotherapy who sustain an acute medical complication. Not surprisingly, chemotherapy and radiation were also associated with longer lengths of stay and increased in-hospital costs. The inverse relationship between palliative care encounters and cancer-directed therapies may be due to patient or physician preferences or a belief that anticancer treatment is not compatible with advance care planning discussions, even in patients in whom the future is predictable. The relationship may also be related to availability of services, as local availability of hospice or palliative care services has been shown to be associated with less aggressive care. 18 Although chemotherapy may be used for palliative purposes, an overwhelming majority of patients with incurable cancer believe that the chemotherapy treatments they are receiving may be curative. 46 Chemotherapy at the end of life in patients with terminal cancer results in minimal or no survival benefit and contributes to disproportionate health-care spending at the end of life. 47, 48 There are several limitations to the use of hospital discharge data, which may influence our findings. The NIS database provides no follow-up data beyond the index admission and is limited to a 30-day postoperative window, and contains no information on stage of disease, grade, subtype, or long-term survival. Thus, a meaningful analysis of long-term outcomes is not possible from the available data. Although comorbidity scores were used for risk classification, the ability to adequately control for case mix is limited when discharge diagnoses from administrative databases are used. Another potential limitation is that the cost analysis was based on hospitalrelated charges, adjusted for institutional expense-torevenue ratios, and did not include physician-related costs or services provided outside of the hospital, as these data are not contained in the NIS database.
We could not determine the availability of palliative care consultative services at the respective hospitals during this time period. As mentioned, we were unable to determine if patients underwent a formal palliative care consultation; beyond the use of the V66.7 code, the only way to determine the incidence of palliative care consultations using administrative data would be to link the Current Procedural Terminology code for an in-patient consultation to the specialty of the consultation physicians. However, the American Academy of Hospice and Palliative Care Medicine reports that there are fewer than 5000 board certified palliative care physicians, 38 suggesting the possibility that, in some cases, the physicians providing in-patient palliative care consultations may not be board-certified palliative care physicians, resulting in underestimation of this type of care. As the NIS is limited to ICD-9 codes only, such analysis cannot be performed.
Nevertheless, these data do demonstrate that in-patient palliative care encounters are uncommon in patients with terminal head and neck cancer and are more common in patients who die in the hospital. Palliative care for patients with terminal head and neck cancer is associated with reduced hospital-related costs, but seems to be underutilized and restricted to the elderly, uninsured, and patients with an increased risk of mortality. Increased use of palliative care services is needed to ensure that such care is used to accomplish the goal of palliation of disease symptoms rather than being used to manage death and complications.
